# 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00929110** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 1066 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Glycopyrronium bromide
- **DRUG:** Placebo to glycopyrronium bromide
- **DRUG:** Tiotropium

## Key facts

- **NCT ID:** NCT00929110
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 1066 (ACTUAL)
- **Last updated:** 2012-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00929110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00929110, "1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00929110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*